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AbstrAct
Atypical haemolytic-uraemic syndrome (aHUS) is a rare cause of thrombotic microangiopathy (TMA). The typical 
form occurs most frequently in children following infection with Shiga-like toxin-producing bacteria, whereas in 
the atypical form genetic mutations affecting complement regulatory proteins involved in the alternative comple-
ment pathway may be identified. The clinical features of aHUS may mimic other causes of TMA such as thrombotic 
thrombocytopenic purpura and malignant hypertension. We present a case of a 67-year-old woman who pre- 
sented with a TMA and discuss the diagnostic challenges that were confronted due to the many overlapping clinical 
and laboratory features of the different causes of this syndrome. Clinicians should be aware of the varied clinical 
manifestations of TMAs to ensure early diagnosis and initiation of appropriate treatment.  
Keywords: thrombotic microangiopathy; atypical haemolytic-uraemic syndrome.
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INtrODUctION
Haemolytic-uraemic syndrome (HUS) is an uncommon 
cause of thrombotic microangiopathy (TMA) in adults 
and has a reported overall incidence of 1–2 cases per 
100,000 population [1]. It is classified into two types, 
namely, typical and atypical HUS. The typical form has a 
reported incidence of 6.2 cases per 100,000 population 
and frequently occurs in children under 5 years of age 
when it is caused by Shiga-like toxin-producing bacteria 
such as Escherichia coli O157:H7 [2].  
Atypical haemolytic-uraemic syndrome (aHUS) is rare 
and is reported to represent 10% of HUS cases [2]. It 
may be familial or sporadic, the latter representing most 
cases. Triggers include infection with HIV, drugs such as 
cyclosporin, malignancies and pregnancy and it may 
follow organ transplantation [3,4]. In half the cases a 
trigger cannot be identif ied. In these cases, genetic 
abnormalities affecting complement-regulatory proteins 
of an alternative complement pathway may be found.
More common causes of thrombotic microangiopathy, 
such as thrombotic thrombocytopenic purpura and 
malignant hypertension, have clinical and biochemical 
similarities to those of aHUS, making the distinction 
between these conditions a diagnostic challenge. 
We present a case of a 67-year-old woman who pre-
sented with TMA and discuss the diagnostic challenges 
that were confronted as a result of many of the over-
lapping clinical and laboratory features of the different 
causes of this syndrome. 
cAsE PrEsENtAtION
A 67-year-old woman, known with schizophrenia for 
the past ten years, was well controlled on medication, 
which included intramuscular fluphenazine 12.5 mg 
monthly, risperidone 0.5 mg daily, promethazine 25 mg 
daily, and thiamine 100 mg daily. She presented to a 
peripheral hospital with hyperactive delirium. There was 
no history of preceding bloody diarrhoea. Her blood 
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table 1.  Laboratory results.
Laboratory test
On 
admission to 
peripheral 
hospital
On 
admission 
to referral 
hospital
Reference 
range
Sodium 139 136 136–145 mmol/L
Potassium 2.8 5.4 3.5–5.1 mmol/L
Urea 7.1 29.3 2.1–7.1 mmol/L
Creatinine 135 655 49–90 µmol/L 
Leukocyte count 3.36 2.80 3.9–12.6 x 109/L
Haemoglobin 8.7 4.5 12.0–15.0 g/dL
Mean cell volume 89.0 107.2 83.1–101.6 fL
Platelets 74 61 186–454 x 109/L
Lactate 
dehydrogenase 
1161 705 110–210 IU/L
Red cell 
fragmentation
20 11 0%
Reticulocyte 
production index
1.4 1.2
1–2 adequate 
response, > 2 
suggestive of 
haemolysis
INR 1.11 1.22 None
PTT 25.3 28.4 22.0–30.7 sec
Fibrinogen 3.1 1.5 2.0–4.0 g/L
Haptoglobin < 0.10 0.00 0.30–2.00 g/L
Coombs test negative –
CRP 20 – 0–10 mg/L
UPCR 1.54 0.28 < 0.1 g/day
ANA – negative
C3 complement – 0.45 0.90–1.80 g/L
C4 complement – 0.30 0.10–0.40 g/L
PR3-ANCA – negative negative
MPO-ANCA – negative negative
Abbreviations: INR, international normalized ratio; PTT, partial thromboplastin 
time; CRP, C-reactive protein; UPCR, urine protein to creatinine ratio; ANA, 
anti-nuclear antibody; ANCA, anti-neutrophilic cytoplasmic antibody; PR3-ANCA, 
anti-proteinase 3; MPO-ANCA, anti-myeloperoxidase.
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pressure (BP) was 170/100 mmHg. No obvious source of 
infection was identif ied on clinical examination and blood 
and urine cultures were negative. Routine blood tests 
revealed features of TMA that included microangiopathic 
haemolytic anaemia (MAHA) with 20% red blood cell 
fragments on peripheral smear, haemoglobin concentration 
of 5.8 g/dL (normal 12.0–15.0 g/dL), lactate dehydrogenase 
of 1161 U/L (normal 110–210 U/L) and thrombocytopaenia 
of 54 x 109/L (normal 186–454 x 109/L). She had renal 
failure with an elevated creatinine of 258 µmol/L (normal 
49–90 µmol/L). Other relevant results are shown in 
Table 1. These laboratory findings, together with her 
neurological symptoms, were suggestive of thrombotic 
thrombocytopenic purpura (TTP) and the patient was 
treated with prednisone (1 mg/kg/day) and fresh frozen 
plasma (30 units administered over 10 days). She did not 
show any improvement and was referred to our hospital 
for further management. 
On presentation to our hospital, she had elevated BP of 
210/120 mmHg. There were no features of hypertensive 
target organ damage, and specifically, no flame-shaped 
haemorrhages, exudates or papilloedema on fundoscopic 
examination. There were no clinical features suggestive 
of a connective tissue disease such as systemic lupus 
erythematosus, scleroderma or anti-phospholipid syn-
drome. Urine examination showed 2+ protein, 3+ blood 
and scanty granular casts. A diagnosis of malignant hyper-
tension was made, and she was started on amlodipine 5 mg 
daily, enalapril 5 mg twice daily and furosemide 80 mg daily. 
Despite 2 weeks of good blood pressure control, features 
of MAHA persisted and the acute kidney injury progressed 
(Table 1). Investigations to screen for causes of an acute 
glomerulonephritis were negative except for low con-
centrations of complement component 3 (C3). The 
Coombs test and disseminated intravascular coagulation 
(DIC) screen were also negative, and the vitamin B12 and 
folate concentrations were in the normal ranges. 
She subsequently had a kidney biopsy that revealed a 
spectrum of thrombotic and angiopathic lesions secondary 
to endothelial injury (Figure 1). Segmental glomerular 
necrosis with mesangiolysis and formation of capillary 
microaneurysms were present. Focal glomerular capillary 
thrombosis with fragmented erythrocytes (schistocytes) 
were also seen. The interlobular arteries showed oede-
matous intimal thickening with luminal narrowing. Immu-
nofluorescence findings were of non-specific granular IgM, 
C3, IgG and IgA glomerular capillary wall staining. Electron 
microscopy showed detachment of endothelial cells from 
glomerular capillary basement membranes with reduplica-
tion of the basement membranes. These findings were 
consistent with a TMA. 
A presumed diagnosis of atypical haemolytic-uraemic 
syndrome (aHUS) was made. The patient was transferred 
back to the referring hospital for conservative management 
due to her overall poor renal prognosis. 
DIscUssION
This case was a diagnostic challenge, and highlights the 
overlapping features of some of the thrombotic micro-
angiopathies. Figure 2 shows the overlapping clinical and 
laboratory features of aHUS, TTP and malignant hyper-
tension. 
Atypical haemolytic-uraemic syndrome
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Our patient was initially diagnosed as having TTP at the 
peripheral hospital. This was a reasonable conclusion since 
she had many of the clinical and laboratory features to 
suggest this diagnosis, such as neurological disturbances 
(delirium), MAHA, thrombocytopenia and renal failure. 
TTP remains a relatively common cause of TMA in South 
Africa, mainly because of the HIV epidemic [5]. Our patient, 
however, was not HIV infected. Additional features that 
did not support a diagnosis of TTP included the minimum 
value of the platelet count and the severity of the acute 
kidney injury. In TTP patients with severely reduced 
ADAMTS-13 activity, platelet counts are usually less than 
30 x 109/L and the serum creatinine usually does not 
exceed 200 µmol/L [6]. In many South African hospitals, 
ADAMTS-13 activity assays are not routinely available and 
delays in obtaining the results may retard diagnosis and 
initiation of therapy. In our patient, neither the platelet 
counts nor the severity of her acute kidney injury supported 
a diagnosis of TTP. 
In addition, her schizophrenia as well as adverse effects 
related to its treatment may have explained her cognitive 
impairment. It is also possible that her delirium may have 
been caused by aHUS itself since up to 20% of patients 
may have extrarenal involvement, including central nervous 
system involvement [7]. 
At our hospital, a diagnosis of malignant hypertension 
was made initially due to the severity of her hyperten- 
sion, the ongoing MAHA and the progressive worsening of 
her acute kidney injury (AKI) despite several days of 
plasma infusion. Her delirium was thought to be due to 
hypertensive encephalopathy. Malignant hypertension has 
recently been defined as extreme elevations of systolic BP 
(> 220 mmHg) and/or diastolic BP (> 130 mmHg) along 
with evidence of target organ damage [8,9]. However, the 
absence of grade III or IV hypertensive retinopathy as well 
as the ongoing MAHA and progressive AKI, despite tight 
blood pressure control, made a diagnosis of malignant 
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Figure 1.  Histological findings on kidney biopsy.  (A) The glomerulus shows thrombosis (asterisk) and segmental necrosis 
with mesangiolysis (arrow) (haematoxylin and eosin, x400 magnification). (B) Complete loss of silver positive mesangial matrix in 
the segment with mesangiolysis (arrow) (Jones methenamine silver, x400 magnification). (C) Oedematous intimal thickening with 
luminal narrowing of an interlobular artery (haematoxylin and eosin, x400 magnification). (D) Peripheral glomerular capillary loop 
shows thin, newly formed basement membrane (arrow) on electron microscopy (x5000 magnification).
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hypertension unlikely. The mild degree of proteinuria also 
made acute glomerulonephritis unlikely as an underlying 
cause of malignant hypertension. 
We considered the diagnosis of aHUS with severe hyper-
tension. A case series of aHUS included 9 patients with 
severe hypertension and renal TMA [10]. All patients had 
mild to moderate hypertensive retinopathy but just one 
had papilloedema. This patient had the highest BP (240/ 
150 mmHg). The mean age of these patients was 39 years 
(range 27–65 years), 56% were female and average BP was 
203/123 mmHg. The mean serum creatinine was 837 
µmol/L (range 162–1730 µmol/L), 78% had haematuria 
and mean protein excretion was 1.7 g per day (range 
0.4–3.9 g per day). Average haemoglobin was 6.5 g/dL 
(range 5.1–8.2 g/dL), average LDH was 875 U/L (range 
165–2125 U/L), 44% had MAHA and the average platelet 
count was 190 x 109/L (range 98–340 x 109/L). All patients 
had identifiable abnormalities involving complement. The 
key message from this paper is that patients presenting 
with severe hypertension and renal TMA may be mis-
diagnosed with malignant hypertension, concealing the true 
diagnosis of aHUS. The authors recommended that all 
patients with severe hypertension and renal TMA be 
investigated for an underlying complement disorder. 
Malignant hypertension with renal TMA and aHUS with 
severe hypertension are likely to be two distinct clinical 
entities  [11]. The clinical findings of grade III or IV hyper-
tensive retinopathy, diastolic BP > 130 mmHg and a good 
response to BP control distinguishes malignant hyperten-
sion from aHUS [11]. The genetic abnormalities of the 
alternative complement pathway found in aHUS have very 
rarely been identif ied in patients with malignant hyper-
tension [11]. Whether genetic mutations of the alternative 
complement pathway are the initiating event in these cases, 
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Figure 2.  Venn diagram illustrating the overlapping and the unique features of atypical haemolytic-uraemic 
syndrome, thrombotic thrombocytopenic purpura and malignant hypertension. 
Abbreviations: aHUS, atypical haemolytic-uraemic syndrome; TTP, thrombotic thrombocytopenic purpura; MAHA, microangio-
pathic haemolytic anaemia; ADAMTS-13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; BP, 
blood pressure.
*Triggers include HIV infection, malignancy, pregnancy, autoimmune disease and drugs. 
Triggers*
Low C3 Moderate to severe thrombocytopenia
Severe 
hypertension and 
renal failure
Hypokalaemia
Mild renal 
failure
Diastolic BP  
> 130 mmHg
Severe 
thrombocytopenia Fever
Grade III/IV
hypertensive 
retinopathy
Reduced 
ADAMTS-13 
activity
MAHA
Encephalopathy
aHUs
Malignant 
hypertension
ttP
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or are merely activated in response to shear stress caused 
by severe hypertension, remains to be answered.      
The diagnosis of aHUS was strongly suspected after the 
finding of low serum C3 with normal C4, which indicated 
activation of the alternative complement pathway. The 
kidney biopsy was performed to seek additional evidence 
in support of the diagnosis since tests to identify genetic 
mutations affecting complement regulatory proteins are 
currently unavailable in South Africa. The histological 
findings of mesangiolysis, glomerular capillary intraluminal 
thrombosis and microaneurysm formation, immune com-
plex deposition along the glomerular capillary wall and 
endothelial cell detachment were similar to those reported 
by Timmermans et al. [10].
Treatment of aHUS involves intensive plasma exchange 
with 1–2 plasma volume exchanges recommended daily 
and should be initiated within 24 hours of diagnosis [12]. 
Additional therapies include steroids, azathioprine, myco-
phenolate mofetil and rituximab. Response to therapy is 
dependent on the type of complement abnormality 
involved. Studies that used plasma exchange reported 
short-term remission rates ranging from 30–80%; however, 
remission was defined as haematological remission but 
with renal consequences that included end-stage renal 
disease [1]. Reported rates of end-stage renal disease are 
60–70%. In patients that receive kidney transplants, as 
many as 50% experience recurrence in the allograft with 
80–90% developing graft failure [1]. Given the high cost of 
plasma exchange, the high rate of end-stage renal disease 
with dialysis-dependence and the high rate of renal allograft 
recurrence and graft failure, a decision was made to manage 
the patient conservatively.
cONcLUsIONs
Atypical HUS may mimic other causes of TMA, particularly 
TTP and malignant hypertension. It is therefore important 
that clinicians are aware of the varied clinical presentations 
of these TMAs to ensure early diagnosis and the initiation 
of appropriate treatment.
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